Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions
Phase 1
- Conditions
- o medical conditionTherapeutic area: Not possible to specify
- Registration Number
- CTIS2024-512912-23-00
- Lead Sponsor
- Bluepharma Industria Farmaceutica S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets does lenvatinib inhibit in the CTIS2024-512912-23-00 bioequivalence trial?
How does Bluepharma's lenvatinib formulation compare to Lenvima in pharmacokinetic parameters under fed conditions?
Are there biomarkers associated with lenvatinib absorption variability in healthy participants of CTIS2024-512912-23-00?
What adverse event profiles are reported for lenvatinib 10 mg capsules in Phase I trials with healthy volunteers?
How does lenvatinib's bioavailability in this trial relate to its use in thyroid cancer and other multi-kinase inhibitor therapies?